This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Park, S.-Y. Articles by Park, Y.-M. Search for Related Content PubMed PubMed Citation Articles by Park, S.-Y. Articles by Park, Y.-M.

Peroxiredoxin 1 Interacts with Androgen Receptor and Enhances Its Transactivation

Departments of ¹ Cell Stress Biology, ² Cancer Chemoprevention, ³ Urologic Oncology, and ⁴ Pathology, Roswell Park Cancer Institute, Buffalo, New York

Requests for reprints: Young-Mee Park, Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263. Phone: 716-845-3190; Fax: 716-845-8899; E-mail: young-mee.park{at}roswellpark.org.

Although hypoxia is accepted as an important microenvironmental factor influencing tumor progression and treatment response, it is usually regarded as a static global phenomenon. Consequently, less attention is given to the impact of dynamic changes in tumor oxygenation in regulating the behavior of cancer cells. Androgen receptor (AR) signaling plays a critical role in prostate cancer. We previously reported that hypoxia/reoxygenation, an in vitro condition used to mimic an unstable oxygenation climate in a tumor, stimulates AR activation. In the present study, we showed that peroxiredoxin 1 (Prx1), a member of the peroxiredoxin protein family, acts as a key mediator in this process. We found that the aggressive LN3, C4-2, and C4-2B prostate cancer cell lines derived from LNCaP possess constitutively elevated Prx1 compared with parental cells, and display greater AR activation in response to hypoxia/reoxygenation. Although the cell survival–enhancing property of Prx1 has traditionally been attributed to its antioxidant activity, the reactive oxygen species–scavenging activity of Prx1 was not essential for AR stimulation because Prx1 itself was oxidized and inactivated by hypoxia/reoxygenation. Increased AR transactivation was observed when wild-type Prx1 or mutant Prx1 (C52S) lacking antioxidant activity was introduced into LNCaP cells. Reciprocal immunoprecipitation, chromatin immunoprecipitation, and in vitro pull-down assays corroborated that Prx1 interacts with AR and enhances its transactivation. We also show that Prx1 is capable of sensitizing a ligand-stimulated AR. Based on the above information, we suggest that disrupting the interaction between Prx1 and AR may serve as a fruitful new target in the management of prostate cancer. [Cancer Res 2007;67(19):9294–303]

This article has been cited by other articles:

				J. H. Seo, J. C. Lim, D.-Y. Lee, K. S. Kim, G. Piszczek, H. W. Nam, Y. S. Kim, T. Ahn, C.-H. Yun, K. Kim, et al. Novel Protective Mechanism against Irreversible Hyperoxidation of Peroxiredoxin: N{alpha}-TERMINAL ACETYLATION OF HUMAN PEROXIREDOXIN II J. Biol. Chem., May 15, 2009; 284(20): 13455 - 13465. [Abstract] [Full Text] [PDF]

				J. A. Graves, M. Metukuri, D. Scott, K. Rothermund, and E. V. Prochownik Regulation of Reactive Oxygen Species Homeostasis by Peroxiredoxins and c-Myc J. Biol. Chem., March 6, 2009; 284(10): 6520 - 6529. [Abstract] [Full Text] [PDF]

				C. Pritchard, B. Mecham, R. Dumpit, I. Coleman, M. Bhattacharjee, Q. Chen, R. A. Sikes, and P. S. Nelson Conserved Gene Expression Programs Integrate Mammalian Prostate Development and Tumorigenesis Cancer Res., March 1, 2009; 69(5): 1739 - 1747. [Abstract] [Full Text] [PDF]

				S. Donnelly, C. M. Stack, S. M. O'Neill, A. A. Sayed, D. L. Williams, and J. P. Dalton Helminth 2-Cys peroxiredoxin drives Th2 responses through a mechanism involving alternatively activated macrophages FASEB J, November 1, 2008; 22(11): 4022 - 4032. [Abstract] [Full Text] [PDF]

				J.-H. Kim, P. N. Bogner, S.-H. Baek, N. Ramnath, P. Liang, H.-R. Kim, C. Andrews, and Y.-M. Park Up-Regulation of Peroxiredoxin 1 in Lung Cancer and Its Implication as a Prognostic and Therapeutic Target Clin. Cancer Res., April 15, 2008; 14(8): 2326 - 2333. [Abstract] [Full Text] [PDF]